

Continuous Bioprocessing Market by Product (Chromatography, Filtration, Bioreactor, Media), Process (Upstream, Downstream), Scale of Operation (Commercial, Clinical), Application (mAbs, Vaccines, Cell & Gene Therapy), & End User - Global Forecast to 2028

Market Report | 2023-11-23 | 263 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The global continuous bioprocessing market is projected to reach USD 599 million by 2028 from USD 218 million in 2023, at a CAGR of 22.4% during the forecast period of 2023 to 2028. The growth of this market can be attributed to the increasing adoption of continuous bioprocessing among CDMOs and CMOs. Continuous bioprocessing is becoming more popular among CDMOs and CMOs for the production of biopharmaceuticals. These organizations face increasing pressure to manufacture biopharmaceuticals faster and more efficiently, and continuous bioprocessing can help them meet this demand. Additionally, continuous bioprocessing is moving into larger-scale projects and new therapeutic areas. This trend is expected to drive the growth of the continuous bioprocessing market in the coming years.

"The monoclonal antibodies segment accounted for the largest share by application in 2022."

In 2022, the monoclonal antibodies segment accounted for the largest share by application in the global continuous bioprocessing market. Continuous bioprocessing is rapidly gaining momentum in monoclonal antibody bioprocessing, providing potential advantages such as smaller facility footprints, lower investment costs, flexibility, and process economy. The commercial success of mammalian cell-derived mAbs has led to the increased demand for novel single-use bioreactor systems that provide greater productivity & flexibility and reduce costs.

"The US has continued to dominate the continuous bioprocessing market during the forecast period of 2023-2028."

The US dominated the continuous bioprocessing market in North America in 2022. The US is the dominant market for biopharmaceuticals, accounting for around a third of the global market. It is the world leader in biopharmaceutical R&D. According to the Pharmaceutical Research and Manufacturers Association (PhRMA), US pharmaceutical firms hold the intellectual property

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

rights for most new medicines and conduct over half the world's R&D in pharmaceuticals. Bioprocessing companies in the US are actively participating in the development of biopharmaceuticals using continuous bioprocessing. These companies are also widely offer perfusion-based products, which offer less turnaround time and are energy-efficient. These factors are supporting the growth of the continuous bioprocessing market in the country.

The primary interviews conducted for this report can be categorized as follows:

- By Respondent: Supply Side- 70% and Demand Side 30%
- By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
- By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10% and Middle East & Africa- 5%

List of Companies Profiled in the Report:

- Thermo Fisher Scientific Inc. (US)
- Danaher Corporation (US)
- Sartorius AG (Germany)
- Thermo Fisher Scientific Inc. (US)
- Repligen Corporation (US)
- Merck KGaA (Germany)
- 3M Company (US)
- Getinge AB (Sweden)
- Eppendorf SE (Germany)
- Corning Incorporated (US)
- Entegris (US)
- FUJIFILM Holdings Corporation (Japan)
- Meissner filtration products, Inc. (US)
- Kuhner AG (Switzerland)
- Esco Lifesciences Group (Singapore)
- SATAKE MultiMix Corporation (Japan)
- Bionet (Spain)
- Stobbe Group (Switzerland)
- bbi-biotech GmbH (Germany)
- OmniBRx Biotechnologies (India)
- Cell Culture Company, LLC (US)
- Pierre Guerin (France)
- Solida Biotech GmbH (Germany)
- Zellwerk GmbH (Germany)
- 3D Biotek, LLC (US)
- FiberCell Systems Inc. (US)

Research Coverage:

This research report categorizes the continuous bioprocessing market by product (chromatography systems and consumables, filtration systems and devices, bioreactors, cell culture media, cell lines, buffers and reagents, and other products), by scale of operation (commercial operations and clinical operations), by process (downstream bioprocess and upstream bioprocess), by application (monoclonal antibodies, vaccines, cell and gene therapy, and other applications), by end users (pharmaceutical & biopharmaceutical companies, contract research organizations (CROs) & contract manufacturing organizations (CMOs), and academic & research institutes) and by region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

opportunities, influencing the growth of the continuous bioprocessing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the continuous bioprocessing market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall continuous bioprocessing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

- Analysis of key drivers (rising demand for biopharmaceuticals, growing adoption among CDMOs and CMOs, advantages of continuous bioprocessing over batch/fed-batch mode, favorable regulatory & government support for innovative technologies, and emergence of integrated end-to-end continuous bioprocessing), restraints (high capital investment to limit entry for small players and stringent regulatory requirements), opportunities (high growth potential of emerging economies and PAT-enabled optimization of continuous bioprocessing), and Challenges (integration into existing manufacturing facilities and operational challenges) influencing the growth of the market.
- Product Development/Innovation: Detailed insights on newly launched products of the continuous bioprocessing market
- Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the continuous bioprocessing market
- Competitive Assessment: Danaher Corporation (US), Sartorius AG (Germany), Thermo Fisher Scientific Inc. (US), Repligen Corporation (US), Merck KGaA (Germany), 3M Company (US), Getinge AB (Sweden), Eppendorf SE (Germany), Corning Incorporated (US), Entegris (US), FUJIFILM Holdings Corporation (Japan), Meissner filtration products, Inc. (US), Kuhner AG (Switzerland), Esco Lifesciences Group (Singapore), SATAKE MultiMix Corporation (Japan), and among others in the market.

Table of Contents:

1□INTRODUCTION□	36
1.1□STUDY OBJECTIVES□	36
1.2□MARKET DEFINITION□	36
1.2.1□INCLUSIONS AND EXCLUSIONS□	37
1.3□MARKET SEGMENTATION□	38
FIGURE 1□CONTINUOUS BIOPROCESSING MARKET SEGMENTATION□	38
1.4□YEARS CONSIDERED□	38
1.5□CURRENCY CONSIDERED□	39
1.6□LIMITATIONS□	39
1.7□STAKEHOLDERS□	39
1.8□RECESSION IMPACT□	40
2□RESEARCH METHODOLOGY□	41
2.1□RESEARCH DATA□	41
FIGURE 2□RESEARCH DESIGN□	41
2.1.1□SECONDARY DATA□	42
2.1.2□PRIMARY DATA□	43
FIGURE 3□CONTINUOUS BIOPROCESSING MARKET: BREAKDOWN OF PRIMARIES□	43
2.2□MARKET SIZE ESTIMATION□	44
FIGURE 4□MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS (2022)□	44
FIGURE 5□MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS)□	45

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

FIGURE 6	ILLUSTRATIVE EXAMPLE OF SARTORIUS AG: REVENUE SHARE ANALYSIS (2022)	45
2.2.1	INSIGHTS FROM PRIMARIES	46
FIGURE 7	MARKET VALIDATION FROM PRIMARY EXPERTS	46
FIGURE 8	MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH	47
2.3	GROWTH FORECAST	48
FIGURE 9	CONTINUOUS BIOPROCESSING MARKET: CAGR PROJECTIONS (2023-2028)	48
FIGURE 10	CONTINUOUS BIOPROCESSING MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	49
2.4	DATA TRIANGULATION & MARKET BREAKDOWN	50
FIGURE 11	DATA TRIANGULATION METHODOLOGY	50
2.5	RESEARCH ASSUMPTIONS	51
2.6	RISK ANALYSIS	51
2.7	RECESSION IMPACT ANALYSIS	51
TABLE 1	GLOBAL INFLATION RATE PROJECTIONS, 2021-2028 (% GROWTH)	51
TABLE 2	US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)	52
TABLE 3	US HEALTH EXPENDITURE, 2023-2030 (USD MILLION)	52
3	EXECUTIVE SUMMARY	53
FIGURE 12	CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)	53
FIGURE 13	CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2023 VS. 2028 (USD MILLION)	54
FIGURE 14	CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2023 VS. 2028 (USD MILLION)	54
FIGURE 15	CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)	55
FIGURE 16	CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)	56
FIGURE 17	GEOGRAPHICAL SNAPSHOT OF CONTINUOUS BIOPROCESSING MARKET	57
4	PREMIUM INSIGHTS	58
4.1	CONTINUOUS BIOPROCESSING MARKET OVERVIEW	58
FIGURE 18	RIISING DEMAND FOR BIOPHARMACEUTICALS TO DRIVE MARKET GROWTH DURING FORECAST PERIOD	58
4.2	NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT	59
FIGURE 19	CHROMATOGRAPHY SYSTEMS & CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022	59
4.3	CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION	60
FIGURE 20	MONOCLONAL ANTIBODIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD	60
4.4	CONTINUOUS BIOPROCESSING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	60
FIGURE 21	CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD	60
5	MARKET OVERVIEW	61
5.1	INTRODUCTION	61
FIGURE 22	CONTINUOUS BIOPROCESSING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	61
5.2	MARKET DYNAMICS	62
TABLE 4	CONTINUOUS BIOPROCESSING MARKET: IMPACT ANALYSIS	62
5.2.1	DRIVERS	63
5.2.1.1	Rising demand for biopharmaceuticals	63
5.2.1.2	Growing adoption among CDMOs and CMOs	63
5.2.1.3	Advantages of continuous bioprocessing over batch/fed-batch mode	64
5.2.1.4	Favorable regulatory & government support for innovative technologies	65
5.2.1.5	Emergence of integrated end-to-end continuous bioprocessing	65
5.2.2	RESTRAINTS	66
5.2.2.1	High capital investments to limit entry for smaller players	66
5.2.2.2	Stringent regulatory requirements	66
5.2.3	OPPORTUNITIES	67

5.2.3.1	High growth potential of emerging economies	67
5.2.3.2	PAT-enabled optimization of continuous bioprocessing	68
5.2.4	CHALLENGES	68
5.2.4.1	Integration into existing manufacturing facilities	68
5.2.4.2	Operational challenges	69
5.3	PRICING ANALYSIS	70
TABLE 5	AVERAGE SELLING PRICE OF CONTINUOUS BIOPROCESSING PRODUCTS, BY KEY PLAYER (2022)	70
TABLE 6	AVERAGE SELLING PRICE OF CONTINUOUS BIOPROCESSING PRODUCTS, BY REGION (2022)	70
5.4	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	71
FIGURE 23	REVENUE SHIFT AND NEW POCKETS FOR CONTINUOUS BIOPROCESSING PRODUCT PROVIDERS	71
5.5	VALUE CHAIN ANALYSIS	72
FIGURE 24	CONTINUOUS BIOPROCESSING MARKET: VALUE CHAIN ANALYSIS	72
5.5.1	RESEARCH & PRODUCT DEVELOPMENT	72
5.5.2	RAW MATERIAL, MANUFACTURING, AND ASSEMBLY	73
5.5.3	DISTRIBUTION AND AFTER-SALES SERVICES	73
5.6	SUPPLY CHAIN ANALYSIS	74
FIGURE 25	CONTINUOUS BIOPROCESSING MARKET: SUPPLY CHAIN ANALYSIS	74
5.7	ECOSYSTEM ANALYSIS	75
FIGURE 26	ECOSYSTEM MARKET MAP: CONTINUOUS BIOPROCESSING MARKET	75
TABLE 7	CONTINUOUS BIOPROCESSING MARKET: ROLE IN ECOSYSTEM (SUPPLY/DEMAND SIDE)	75
5.8	PATENT ANALYSIS	77
FIGURE 27	PATENT APPLICATIONS FOR CONTINUOUS BIOPROCESSING MARKET (JANUARY 2013-SEPTEMBER 2023)	77
5.9	KEY CONFERENCES AND EVENTS	78
TABLE 8	CONTINUOUS BIOPROCESSING MARKET: DETAILED LIST OF CONFERENCES AND EVENTS (2023-2024)	78
5.10	REGULATORY LANDSCAPE	79
5.10.1	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	79
TABLE 9	NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	79
TABLE 10	EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	79
TABLE 11	ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	80
TABLE 12	REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	80
5.10.2	REGULATORY GUIDELINES	80
5.11	PORTER'S FIVE FORCES ANALYSIS	81
TABLE 13	CONTINUOUS BIOPROCESSING MARKET: PORTER'S FIVE FORCES ANALYSIS	81
5.11.1	THREAT OF NEW ENTRANTS	82
5.11.2	THREAT OF SUBSTITUTES	82
5.11.3	BARGAINING POWER OF SUPPLIERS	82
5.11.4	BARGAINING POWER OF BUYERS	82
5.11.5	INTENSITY OF COMPETITIVE RIVALRY	82
5.12	TECHNOLOGY ANALYSIS	82
5.13	KEY STAKEHOLDERS AND BUYING CRITERIA	84
FIGURE 28	INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR CONTINUOUS BIOPROCESSING PRODUCTS	84
5.14	KEY BUYING CRITERIA, BY END USER	85
FIGURE 29	KEY BUYING CRITERIA OF END USERS IN CONTINUOUS BIOPROCESSING MARKET	85
6	CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT	86
6.1	INTRODUCTION	87
TABLE 14	CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	87
6.2	CHROMATOGRAPHY SYSTEMS AND CONSUMABLES	88

6.2.1 ADVANTAGES OF HIGH PRODUCTIVITY AND AFFORDABILITY TO DRIVE MARKET 88

TABLE 15 CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY REGION, 2021-2028 (USD MILLION) 88

TABLE 16 NORTH AMERICA: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 89

TABLE 17 EUROPE: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 89

TABLE 18 ASIA PACIFIC: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 89

TABLE 19 LATIN AMERICA: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 90

TABLE 20 MIDDLE EAST & AFRICA: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY REGION, 2021-2028 (USD MILLION) 90

6.3 FILTRATION SYSTEMS AND DEVICES 90

6.3.1 RISING TECHNOLOGICAL ADVANCEMENTS IN FILTRATION SYSTEMS TO DRIVE MARKET 90

TABLE 21 FILTRATION SYSTEMS AND DEVICES MARKET, BY REGION, 2021-2028 (USD MILLION) 91

TABLE 22 NORTH AMERICA: FILTRATION SYSTEMS AND DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 91

TABLE 23 EUROPE: FILTRATION SYSTEMS AND DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 92

TABLE 24 ASIA PACIFIC: FILTRATION SYSTEMS AND DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 92

TABLE 25 LATIN AMERICA: FILTRATION SYSTEMS AND DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 92

TABLE 26 MIDDLE EAST & AFRICA: FILTRATION SYSTEMS AND DEVICES MARKET, BY REGION, 2021-2028 (USD MILLION) 93

6.4 BIOREACTORS 93

6.4.1 ABILITY TO ENABLE PROCESS INTENSIFICATION TO BOOST DEMAND 93

TABLE 27 BIOREACTORS MARKET, BY REGION, 2021-2028 (USD MILLION) 94

TABLE 28 NORTH AMERICA: BIOREACTORS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 94

TABLE 29 EUROPE: BIOREACTORS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 94

TABLE 30 ASIA PACIFIC: BIOREACTORS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 95

TABLE 31 LATIN AMERICA: BIOREACTORS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 95

TABLE 32 MIDDLE EAST & AFRICA: BIOREACTORS MARKET, BY REGION, 2021-2028 (USD MILLION) 95

6.5 CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS 96

6.5.1 INNOVATIONS IN CELL LINE DEVELOPMENT TO SUPPORT MARKET GROWTH 96

TABLE 33 CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION) 97

TABLE 34 NORTH AMERICA: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 97

TABLE 35 EUROPE: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 97

TABLE 36 ASIA PACIFIC: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 98

TABLE 37 LATIN AMERICA: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 98

TABLE 38 MIDDLE EAST & AFRICA: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION) 98

6.6 OTHER PRODUCTS 99

TABLE 39 OTHER PRODUCTS MARKET, BY REGION, 2021-2028 (USD MILLION) 100

TABLE 40 NORTH AMERICA: OTHER PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 100

TABLE 41 EUROPE: OTHER PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 100

TABLE 42 ASIA PACIFIC: OTHER PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 101

TABLE 43 LATIN AMERICA: OTHER PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 101

TABLE 44 MIDDLE EAST & AFRICA: OTHER PRODUCTS MARKET, BY REGION, 2021-2028 (USD MILLION) 101

7 CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION 102

7.1 INTRODUCTION 103

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 45	CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)	103
7.2	COMMERCIAL OPERATIONS	103
7.2.1	GROWING FOCUS ON COST-REDUCTION OF BIOSIMILARS TO PROPEL MARKET	103
TABLE 46	CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY REGION, 2021-2028 (USD MILLION)	104
TABLE 47	NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION)	104
TABLE 48	EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION)	105
TABLE 49	ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION)	105
TABLE 50	LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION)	105
TABLE 51	MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY REGION, 2021-2028 (USD MILLION)	106
7.3	CLINICAL OPERATIONS	106
7.3.1	INNOVATIONS IN R&D TESTING FOR THERAPEUTIC EFFICACY TO DRIVE MARKET	106
TABLE 52	CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY REGION, 2021-2028 (USD MILLION)	107
TABLE 53	NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION)	107
TABLE 54	EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION)	107
TABLE 55	ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION)	108
TABLE 56	LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION)	108
TABLE 57	MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY REGION, 2021-2028 (USD MILLION)	108
8	CONTINUOUS BIOPROCESSING MARKET, BY PROCESS	109
8.1	INTRODUCTION	110
TABLE 58	CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)	110
8.2	DOWNSTREAM BIOPROCESS	110
8.2.1	RIISING TECHNOLOGICAL ADVANCEMENTS SUCH AS SPTFF AND MULTICOLUMN CHROMATOGRAPHY TO PROPEL MARKET	110
TABLE 59	CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY REGION, 2021-2028 (USD MILLION)	111
TABLE 60	NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY COUNTRY, 2021-2028 (USD MILLION)	111
TABLE 61	EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY COUNTRY, 2021-2028 (USD MILLION)	112
TABLE 62	ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY COUNTRY, 2021-2028 (USD MILLION)	112
TABLE 63	LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY COUNTRY, 2021-2028 (USD MILLION)	112
TABLE 64	MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY REGION, 2021-2028 (USD MILLION)	113
8.3	UPSTREAM BIOPROCESS	113
8.3.1	ADOPTION OF PERFUSION TECHNOLOGY TO SUPPORT MARKET GROWTH	113
TABLE 65	CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY REGION, 2021-2028 (USD MILLION)	114
TABLE 66	NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY COUNTRY, 2021-2028 (USD	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

MILLION) 114

TABLE 67 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY COUNTRY, 2021-2028 (USD MILLION) 114

TABLE 68 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY COUNTRY, 2021-2028 (USD MILLION) 115

TABLE 69 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY COUNTRY, 2021-2028 (USD MILLION) 115

TABLE 70 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY REGION, 2021-2028 (USD MILLION) 115

9 CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION 116

9.1 INTRODUCTION 117

TABLE 71 CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 117

9.2 MONOCLONAL ANTIBODIES 117

9.2.1 GROWING FOCUS ON THERAPEUTIC APPLICATIONS TO PROPEL MARKET 117

TABLE 72 CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021-2028 (USD MILLION) 118

TABLE 73 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION) 118

TABLE 74 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION) 119

TABLE 75 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION) 119

TABLE 76 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION) 119

TABLE 77 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021-2028 (USD MILLION) 120

9.3 VACCINES 120

9.3.1 USE OF PERFUSION BIOREACTORS FOR VACCINE PRODUCTION TO DRIVE MARKET 120

TABLE 78 CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY REGION, 2021-2028 (USD MILLION) 121

TABLE 79 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION) 121

TABLE 80 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION) 121

TABLE 81 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION) 122

TABLE 82 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION) 122

TABLE 83 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY REGION, 2021-2028 (USD MILLION) 122

9.4 CELL & GENE THERAPY 123

9.4.1 INCREASING NUMBER OF CLINICAL TRIALS TO BOOST DEMAND 123

TABLE 84 CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY REGION, 2021-2028 (USD MILLION) 123

TABLE 85 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION) 124

TABLE 86 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION) 124

TABLE 87 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION) 124

TABLE 88 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION) 125

TABLE 89 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY REGION, 2021-2028 (USD MILLION) 125

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

9.5 OTHER APPLICATIONS 125

TABLE 90 CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY REGION, 2021-2028 (USD MILLION) 126

TABLE 91 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 126

TABLE 92 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 126

TABLE 93 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 127

TABLE 94 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 127

TABLE 95 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY REGION, 2021-2028 (USD MILLION) 127

10 CONTINUOUS BIOPROCESSING MARKET, BY END USER 128

10.1 INTRODUCTION 129

TABLE 96 CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION) 129

10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 129

10.2.1 RISING DEMAND FOR BIOLOGICS AND BIOSIMILARS TO DRIVE MARKET 129

TABLE 97 CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2028 (USD MILLION) 130

TABLE 98 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) 130

TABLE 99 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) 131

TABLE 100 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) 131

TABLE 101 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) 131

TABLE 102 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2028 (USD MILLION) 132

10.3 CONTRACT RESEARCH ORGANIZATIONS (CROs) AND CONTRACT MANUFACTURING ORGANIZATIONS (CMOs) 132

10.3.1 RISING OUTSOURCING OF R&D SERVICES BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO PROPEL MARKET 132

TABLE 103 CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2021-2028 (USD MILLION) 133

TABLE 104 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 133

TABLE 105 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 134

TABLE 106 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 134

TABLE 107 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 135

TABLE 108 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2021-2028 (USD MILLION) 135

10.4 ACADEMIC & RESEARCH INSTITUTES 135

10.4.1 COLLABORATIONS BETWEEN PHARMACEUTICAL MANUFACTURERS AND RESEARCH INSTITUTES TO SUPPORT MARKET GROWTH 135

TABLE 109 CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

MILLION) 136

TABLE 110 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION) 136

TABLE 111 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION) 137

TABLE 112 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION) 137

TABLE 113 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION) 137

TABLE 114 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION) 138

11 CONTINUOUS BIOPROCESSING MARKET, BY REGION 139

11.1 INTRODUCTION 140

TABLE 115 CONTINUOUS BIOPROCESSING MARKET, BY REGION, 2021-2028 (USD MILLION) 140

11.2 NORTH AMERICA 140

FIGURE 30 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET SNAPSHOT 141

TABLE 116 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 142

TABLE 117 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 142

TABLE 118 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION) 142

TABLE 119 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION) 143

TABLE 120 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 143

TABLE 121 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION) 143

11.2.1 US 144

11.2.1.1 High biopharmaceutical R&D spending to drive market 144

TABLE 122 US: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 144

TABLE 123 US: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION) 145

TABLE 124 US: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION) 145

TABLE 125 US: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 145

TABLE 126 US: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION) 146

11.2.2 CANADA 146

11.2.2.1 Growing establishment of biopharmaceutical manufacturing facilities to propel market 146

TABLE 127 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 147

TABLE 128 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION) 147

TABLE 129 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION) 147

TABLE 130 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 148

TABLE 131 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION) 148

11.2.3 NORTH AMERICA: RECESSION IMPACT 148

11.3 EUROPE 149

TABLE 132 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 149

TABLE 133 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 150

TABLE 134 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION) 150

TABLE 135 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION) 150

TABLE 136 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 151

TABLE 137 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION) 151

11.3.1 GERMANY 151

11.3.1.1 Increasing initiatives for life sciences research to boost demand 151

TABLE 138 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 152

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 139	GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)	153
TABLE 140	GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)	153
TABLE 141	GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	153
TABLE 142	GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)	154
11.3.2	UK	154
11.3.2.1	Favorable government support for biotech clusters to propel market	154
TABLE 143	UK: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	155
TABLE 144	UK: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)	155
TABLE 145	UK: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)	155
TABLE 146	UK: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	156
TABLE 147	UK: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)	156
11.3.3	FRANCE	156
11.3.3.1	Rising demand for mAbs and biologics to drive market	156
TABLE 148	FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	157
TABLE 149	FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)	157
TABLE 150	FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)	157
TABLE 151	FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	158
TABLE 152	FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)	158
11.3.4	ITALY	158
11.3.4.1	Growth in pharma & biopharma industries to boost demand	158
TABLE 153	ITALY: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	159
TABLE 154	ITALY: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)	159
TABLE 155	ITALY: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)	160
TABLE 156	ITALY: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	160
TABLE 157	ITALY: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)	160
11.3.5	SPAIN	161
11.3.5.1	Increasing R&D funding by academic institutes to support market growth	161
TABLE 158	SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	161
TABLE 159	SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)	162
TABLE 160	SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)	162
TABLE 161	SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	162
TABLE 162	SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)	163
11.3.6	REST OF EUROPE	163
TABLE 163	REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	164
TABLE 164	REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)	164
TABLE 165	REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)	164
TABLE 166	REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	165
TABLE 167	REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)	165
11.3.7	EUROPE: RECESSION IMPACT	165
11.4	ASIA PACIFIC	166
FIGURE 31	ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET SNAPSHOT	167
TABLE 168	ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	168
TABLE 169	ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	168
TABLE 170	ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)	169
TABLE 171	ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)	169
TABLE 172	ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	169
TABLE 173	ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)	170

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.4.1 CHINA 170

11.4.1.1 Government support and rising private investments to drive market growth 170

TABLE 174 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 171

TABLE 175 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION) 171

TABLE 176 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION) 171

TABLE 177 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 172

TABLE 178 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION) 172

11.4.2 JAPAN 172

11.4.2.1 Stringent regulatory guidelines for pharmaceutical drug safety to support market growth 172

TABLE 179 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 173

TABLE 180 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION) 174

TABLE 181 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION) 174

TABLE 182 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 174

TABLE 183 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION) 175

11.4.3 INDIA 175

11.4.3.1 Growth in pharmaceutical industry to boost demand 175

TABLE 184 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 176

TABLE 185 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION) 176

TABLE 186 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION) 176

TABLE 187 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 177

TABLE 188 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION) 177

11.4.4 SOUTH KOREA 177

11.4.4.1 Rising focus on quality manufacturing practices to drive market 177

TABLE 189 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 178

TABLE 190 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION) 179

TABLE 191 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION) 179

TABLE 192 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 179

TABLE 193 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION) 180

11.4.5 REST OF ASIA PACIFIC 180

TABLE 194 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 181

TABLE 195 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION) 181

TABLE 196 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION) 181

TABLE 197 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 182

TABLE 198 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION) 182

11.4.6 ASIA PACIFIC: RECESSION IMPACT 182

11.5 LATIN AMERICA 183

TABLE 199 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 183

TABLE 200 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 184

TABLE 201 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION) 184

TABLE 202 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION) 184

TABLE 203 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 185

TABLE 204 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION) 185

11.5.1 BRAZIL 185

11.5.1.1 Rising focus on cell & therapy manufacturing to support market 185

TABLE 205 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 186

TABLE 206 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION) 186

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 207	BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)	186
TABLE 208	BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	187
TABLE 209	BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)	187
11.5.2	MEXICO	187
11.5.2.1	Increasing expansion of pharmaceutical companies to support market growth	187
TABLE 210	MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	188
TABLE 211	MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)	188
TABLE 212	MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)	188
TABLE 213	MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	189
TABLE 214	MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)	189
11.5.3	REST OF LATIN AMERICA	189
TABLE 215	REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	190
TABLE 216	REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)	190
TABLE 217	REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)	190
TABLE 218	REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	191
TABLE 219	REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)	191
11.5.4	LATIN AMERICA: RECESSION IMPACT	191

Continuous Bioprocessing Market by Product (Chromatography, Filtration, Bioreactor, Media), Process (Upstream, Downstream), Scale of Operation (Commercial, Clinical), Application (mAbs, Vaccines, Cell & Gene Therapy), & End User - Global Forecast to 2028

Market Report | 2023-11-23 | 263 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	2025-05-21
		Signature	<div></div>